Cargando…

The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR(+) CD8(+) effector state and its deletion improves checkpoint blockade

T cell exhaustion (T(EX)) impairs the ability of T cells to clear chronic infection or cancer. While exhausted T cells are hypofunctional, some exhausted T cells retain effector gene signatures, a feature that is associated with expression of KLRs (killer lectin-like receptors). Although KLR(+) T ce...

Descripción completa

Detalles Bibliográficos
Autores principales: McClory, Susan E., Bardhan, Oishi, Rome, Kelly S., Giles, Josephine R., Baxter, Amy E., Xu, Lanwei, Gimotty, Phyllis A., Faryabi, Robert B., Wherry, E. John, Pear, Warren S., Jordan, Martha S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948998/
https://www.ncbi.nlm.nih.gov/pubmed/36824931
http://dx.doi.org/10.1101/2023.02.16.528833
Descripción
Sumario:T cell exhaustion (T(EX)) impairs the ability of T cells to clear chronic infection or cancer. While exhausted T cells are hypofunctional, some exhausted T cells retain effector gene signatures, a feature that is associated with expression of KLRs (killer lectin-like receptors). Although KLR(+) T cells may improve control of chronic antigen, the signaling molecules regulating this population are poorly understood. Using scRNA-seq, flow cytometry, RNA velocity, and scTCR-seq, we demonstrate that deleting the pseudokinase Trib1 shifts T(EX) towards CX3CR1(+) intermediates (T(INT)) with robust enrichment of KLR(+)CD8(+) T cells (T(KLR)) via clonal T cell expansion. These changes are associated with globally increased KLR gene expression throughout the exhaustion program. Further, Trib1 loss augments anti-PD-L1 blockade to improve viral clearance by expanding the T(KLR) population. Together, these data identify Trib1 as an important regulator of T cell exhaustion whose targeting enhances the KLR(+) effector state and improves the response to checkpoint inhibitor therapy.